NCT02818426View on ClinicalTrials.gov

Universal Cancer Peptide-based Vaccination in Metastatic NSCLC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

April 20, 2016

Primary Completion Date

August 30, 2022

Study Completion Date

December 31, 2024

Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
DRUG

UCPVax

Trial Locations (5)

21079

Centre Georges François Leclerc, Dijon

25030

Centre Hospitalier Régional Universitaire de Besançon, Besançon

67091

Hôpitaux Universitaires de Strasbourg, Strasbourg

Unknown

Hôpital Emile Muller, Mulhouse

St Louis Hospital, Paris

Sponsors

Collaborators (1)

Invectys
All Listed Sponsors
collaborator

Invectys

INDUSTRY

lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT02818426 - Universal Cancer Peptide-based Vaccination in Metastatic NSCLC | Biotech Hunter | Biotech Hunter